

## **REACH: non-regulatory announcement**

**Nuformix plc**  
("Nuformix", the "Company" or the "Group")

### **Initiation of research by Allenby Capital**

**Cambridge, UK – 11 March 2021:** Nuformix plc (LSE:NFX), a pharmaceutical development company and drug re-purposing specialist, is pleased to announce the initiation of research by Allenby Capital Limited, the Company's broker.

The research is available on the Allenby Capital website here:

[Allenby Capital](#)

### **Enquiries:**

#### **Nuformix plc**

Dr Anne Brindley, CEO  
Fleur Wood, Investor Relations

+44 (0)1223 627222

#### **Allenby Capital Limited**

Tim Sohal / Matt Butlin (Sales and Corporate Broking)  
Nick Athanas / George Payne (Corporate Finance)

+44 (0)203 328 5656

### **About Nuformix**

Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities.

For more information, please visit [www.nuformix.com](http://www.nuformix.com).

### **About Reach announcements**

This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted companies to distribute media only / non-regulatory news releases into the public domain.